Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rociletinib, a third generation EGFR tyrosine kinase inhibitor: current data and future directions.

Expert opinion on pharmacotherapy - 1 Jan 2016

Chuang Jody C, Salahudeen Ameen A, Wakelee Heather A

Abstract excerpt

INTRODUCTION: Major advances have been made since the discovery of driver mutations and their targeted therapies, especially in the treatment of patients with epidermal growth factor receptor (EGFR) mutations. Despite their initial efficacy in the majority of the patients with such driver mutations, all targeted therapies are limited by the eventual development of resistance mechanisms. AREAS COVERED: EGFR T790M...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials as Topic

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Protein Kinase Inhibitors

Share to Pyrimidines

Source

Identifiers

PMID: 26950414
DOI: 10.1517/14656566.2016.1162786

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rociletinib, a third generation EGFR tyrosine kinase inhibitor: current data and future directions.PMID 26950414Read ↗

[3rd generation's TKI in lung cancer non-small cell EGFR-mutated having acquired a secondary T790M resistance].Semantic proximity Read ↗

From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLCSemantic proximity Read ↗

Rociletinib in EGFR-mutated non-small-cell lung cancer.Semantic proximity Read ↗

The Next Wave of EGFR Tyrosine Kinase Inhibitors Enter the Clinic.Semantic proximity Read ↗

EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance.Semantic proximity Read ↗

Third generation EGFR TKIs: current data and future directions.Semantic proximity Read ↗

Third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.Semantic proximity Read ↗

3009 Activity of rociletinib in EGFR mutant NSCLC patients with a history of CNS involvementSemantic proximity Read ↗

Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686).Semantic proximity Read ↗

Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors.Semantic proximity Read ↗

Efficacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b Study.Semantic proximity Read ↗

Clinical Implications of the T790M Mutation in Disease Characteristics and Treatment Response in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.